Liposomal Eribulin Shows First-Line Antitumor Activity in Advanced HER2-Negative Breast Cancer
A phase 1 expansion cohort demonstrated meaningful antitumor responses and manageable safety for liposomal eribulin as first-line chemotherapy in metastatic ...










